190 related articles for article (PubMed ID: 26283036)
1. Imatinib in advanced chordoma: A retrospective case series analysis.
Hindi N; Casali PG; Morosi C; Messina A; Palassini E; Pilotti S; Tamborini E; Radaelli S; Gronchi A; Stacchiotti S
Eur J Cancer; 2015 Nov; 51(17):2609-14. PubMed ID: 26283036
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of imatinib in advanced chordoma.
Stacchiotti S; Longhi A; Ferraresi V; Grignani G; Comandone A; Stupp R; Bertuzzi A; Tamborini E; Pilotti S; Messina A; Spreafico C; Gronchi A; Amore P; Vinaccia V; Casali PG
J Clin Oncol; 2012 Mar; 30(9):914-20. PubMed ID: 22331945
[TBL] [Abstract][Full Text] [Related]
3. Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study.
Stacchiotti S; Morosi C; Lo Vullo S; Casale A; Palassini E; Frezza AM; Dinoi G; Messina A; Gronchi A; Cavalleri A; Venturelli E; Morelli D; Pilotti S; Collini P; Brich S; Tamborini E; Mariani L; Casali PG
Cancer; 2018 Oct; 124(20):4056-4063. PubMed ID: 30216418
[TBL] [Abstract][Full Text] [Related]
4. Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network.
Baldi GG; Lo Vullo S; Grignani G; Vincenzi B; Badalamenti G; Mastore M; Buonomenna C; Morosi C; Barisella M; Frezza AM; Provenzano S; Simeone N; Picozzi F; Mariani L; Casali PG; Stacchiotti S
Cancer; 2022 Apr; 128(7):1439-1448. PubMed ID: 35026050
[TBL] [Abstract][Full Text] [Related]
5. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Lebellec L; Chauffert B; Blay JY; Le Cesne A; Chevreau C; Bompas E; Bertucci F; Cupissol D; Fabbro M; Saada-Bouzid E; Duffaud F; Feuvret L; Bonneville-Levard A; Bay JO; Vauleon E; Vinceneux A; Noel G; Penel N; Mir O
Eur J Cancer; 2017 Jul; 79():119-128. PubMed ID: 28478340
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses.
Lebellec L; Aubert S; Zaïri F; Ryckewaert T; Chauffert B; Penel N
Crit Rev Oncol Hematol; 2015 Jul; 95(1):125-31. PubMed ID: 25682222
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate in chordoma.
Casali PG; Messina A; Stacchiotti S; Tamborini E; Crippa F; Gronchi A; Orlandi R; Ripamonti C; Spreafico C; Bertieri R; Bertulli R; Colecchia M; Fumagalli E; Greco A; Grosso F; Olmi P; Pierotti MA; Pilotti S
Cancer; 2004 Nov; 101(9):2086-97. PubMed ID: 15372471
[TBL] [Abstract][Full Text] [Related]
9. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).
Rubió-Casadevall J; Martinez-Trufero J; Garcia-Albeniz X; Calabuig S; Lopez-Pousa A; Del Muro JG; Fra J; Redondo A; Lainez N; Poveda A; Valverde C; De Juan A; Sevilla I; Casado A; Andres R; Cruz J; Martin-Broto J; Maurel J;
Ann Surg Oncol; 2015 Sep; 22(9):2948-57. PubMed ID: 25608769
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.
Ha HT; Lee JS; Urba S; Koenig RJ; Sisson J; Giordano T; Worden FP
Thyroid; 2010 Sep; 20(9):975-80. PubMed ID: 20718683
[TBL] [Abstract][Full Text] [Related]
14. Phase II study on lapatinib in advanced EGFR-positive chordoma.
Stacchiotti S; Tamborini E; Lo Vullo S; Bozzi F; Messina A; Morosi C; Casale A; Crippa F; Conca E; Negri T; Palassini E; Marrari A; Palmerini E; Mariani L; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2013 Jul; 24(7):1931-1936. PubMed ID: 23559153
[TBL] [Abstract][Full Text] [Related]
15. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
16. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers.
Stacchiotti S; Casali PG; Lo Vullo S; Mariani L; Palassini E; Mercuri M; Alberghini M; Pilotti S; Zanella L; Gronchi A; Picci P
Ann Surg Oncol; 2010 Jan; 17(1):211-9. PubMed ID: 19847568
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.
Yam C; Murthy RK; Rauch GM; Murray JL; Walters RS; Valero V; Brewster AM; Bast RC; Booser DJ; Giordano SH; Esteva FJ; Yang W; Hortobagyi GN; Moulder SL; Arun B
Invest New Drugs; 2018 Dec; 36(6):1103-1109. PubMed ID: 30311036
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
20. Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma.
Sautter L; Hofheinz R; Tuettenberg J; Grimm M; Vajkoczy P; Groden C; Schmieder K; Hochhaus A; Wenz F; Giordano FA
Oncology; 2020; 98(1):16-22. PubMed ID: 31514200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
